Early Access — free while we kick the tires
EdgarHawk

Dennis Matheis

Director

Director

Latest: Director buying · May 2026

3 filings analyzed · 1 company · Latest 2026-05-21

Companies

Company Buys Sells Direction
Lucid Diagnostics Inc. LUCD 5 0 Net buying

Activity

May 2026
2026-05-21 Lucid Diagnostics Inc. LUCD
medium
Buy
245,000 shares
$245,270
Significance 4/10

Director Dennis Matheis bought 245,000 shares of LUCD at $1.00 on 2026-05-20, raising holdings to 1.03M shares (+31.1%).

Dennis Matheis (Director) purchased 245,000 shares at $1.00, expanding his holdings by +31.1% to 1,033,443 shares. The stock is currently trading at $1.00, down -41.2% from its 52-week high of $1.70 and down -21.9% over the past 30 days. Matheis has a mixed track record at this ticker: of his 4 prior trades at LUCD, only 1 (the August 2025 buy) showed a positive 90-day return (+3.1%), while the other three purchases have generated losses ranging from -2.7% to -24.9% at the 90-day mark. This current purchase follows a pattern of repeated accumulation at declining prices, with his most recent prior transaction occurring one year earlier (May 20, 2025) at the same price point. The company remains unprofitable, reporting a net loss of $-13,909,000.00 in its latest quarter against quarterly revenue of $1,256,000.00.

August 2025
2025-08-22 Lucid Diagnostics Inc. LUCD
medium
Buy
100,000 shares
$101,840
Significance 3/10

Director Matheis Dennis bought 100,000 shares of LUCD at $1.02; stock down 30.8% in 90 days, his three prior buys at this ticker all negative.

Matheis Dennis, a director, purchased 100,000 shares (100.0K shares) at $1.02 on 2025-08-20, increasing his holdings by 17.7% to 665,443 shares (665.4K shares). The timing warrants attention: the stock has declined 30.8% over the past 90 days and is currently 33.3% below its 52-week high of $1.65. More significantly, Dennis's three prior purchases at LUCD (on 2025-05-20, 2025-05-21, and 2025-05-22) all resulted in negative 90-day returns ranging from -21.9% to -24.9%, with a 0.00% win rate over 90-day periods at this ticker. The company remains unprofitable with a net income of $-4,439,000.00 ($-4.4M) in its latest quarter, though it reported strong annual revenue growth of 79.0%. The pattern of consecutive purchases into a declining stock without measurable success over the 90-day horizon suggests this transaction should be evaluated carefully against the documented outcomes of the insider's recent trades at the same ticker.

May 2025
2025-05-22 Lucid Diagnostics Inc. LUCD
high
Buy
350,000 shares
$457,607
Significance 6/10

Director Matheis Dennis purchased 350,000 shares at blended avg $1.31 over 3 days, accumulating initial 350.0K share position at LUCD.

Director Matheis Dennis executed 3 separate purchases totaling 350,000 shares for $457,606.58 across May 20–22, establishing a new director position at a blended average price of $1.31 per share. The company is currently unprofitable with a net income of $-26,908,000 over its most recent full fiscal year, though it posted strong annual revenue growth of +79.0%. At the current price of $1.33, the acquisition is marginally above his blended entry cost, and the stock remains -19.4% from its 52-week high of $1.65. This accumulation by a new director warrant scrutiny into the motivations and timing, particularly given the company's significant operating losses and the size of the position relative to the public float.

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access